|Bid||77.01 x 900|
|Ask||77.20 x 1400|
|Day's Range||75.96 - 77.07|
|52 Week Range||60.32 - 80.74|
|Beta (3Y Monthly)||0.83|
|PE Ratio (TTM)||52.23|
|Forward Dividend & Yield||1.28 (1.61%)|
|1y Target Est||N/A|
Here are the top paid CEOs by state for 2018, as calculated by The Associated Press and Equilar, an executive data firm. The survey considered only publicly traded companies with more than $1 billion in ...
Prepare for more churn around these levels, said Mark Tepper , president of Strategic Wealth Partners. "We're really trying to target good companies that are big players in investible themes, and health care as a sector has struggled this year but it's been resilient over the past month. As the S&P 500 has tumbled 4% this month, the XLV health care sector ETF has held slightly positive.
Is Abbott Laboratories (NYSE:ABT) a good dividend stock? How would you know? Dividend paying companies with growing...
As uncertainty over the outcome of Sino-American trade talks grows, so does the possibility of a longer-than-expected negotiations or an all-out trade war, strategists at Goldman Sachs are providing some timely trading strategies.
Abbott (ABT) is attracting constant attention with developments in its flagship, sensor-based continuous glucose monitoring (CGM) system called FreeStyle Libre System.
Abbott (ABT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Zacks Analyst Blog Highlights: Verizon, Abbott, Illinois Tool Works, Moody's and Baker Hughes
Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.
LONDON/BEIJING, May 7 (Reuters) - Nestle plans to launch a new line of baby formula in China this year under an existing brand, targeted at smaller cities, as the world's largest packaged food company tries to lengthen its lead in the world's biggest baby milk market. The new line, discussed exclusively with Reuters, will focus on smaller provincial cities, often in China's western provinces, where greater shipping distances and lower incomes can make some imported brand goods unaffordable, though wealth there is growing. Producers of many consumer staples such as soft drinks and soap had to seek growth in the less-profitable provincial cities years ago, as China's richer eastern markets matured.
Abbott Laboratories NYSE:ABTView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for ABT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABT. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $643 million over the last one-month into ETFs that hold ABT are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. ABT credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Luminex (LMNX) Q1 results gain from higher revenues from System sales, Royalty as well as Service segments. However, contraction in gross margin remains a woe.
The "Halftime Report" traders answer viewer questions on Abbott Labs, Pinterest, Chevron, and Intel.